In a Phase III trial, treatment with the targeted cancer drug venetoclax in combination with rituximab more than doubled the likelihood that patients with chronic lymphocytic leukaemia (CLL) would survive for two years without cancer progression compared...
Original Article: ASH 2017: Targeted leukaemia drug venetoclax found superior to standard chemotherapy for broad range of patients when combined with rituximab
NEXT ARTICLE